The Effect of Appethyl® vs Placebo on Human Health (Appethyl)

NCT ID: NCT05095038

Last Updated: 2023-07-03

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 82 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-02-10
• Study Completion Date: 2023-06-21

Brief Summary

The study will be conducted as a 26-week double-blinded randomized placebo-controlled trial of Appethyl® vs placebo in 100 overweight/obese (BMI ≥25.0-35.9 kg/m^2) men and women between 18-65 years with prediabetes (fasting plasma glucose of 5.6 mmol/L to <7.0 mmol/L). At initiation, all subjects will receive healthy life style instructions in accordance to the guidelines described in the Nordic Nutrition Recommendations.

The study aim to investigate the effect over time (26-weeks) of daily Appethyl® treatment compared to placebo on change in fasting glucose (primary endpoint) and several other health markers (secondary endpoint).

The hypothesis to be tested is whether the null hypothesis (no difference between Appethyl® and placebo with regard to endpoint data) can be rejected.

Conditions

Overweight and Obesity; PreDiabetes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Appethyl®

Participants are instructed to ingest 10 capsules daily and they are instructed to swallow the capsules in whole with a glass of water with/during lunchtime throughout the study period of 26 weeks.

Each capsule contain 0.5 g Appethyl®, and the daily intake is 5 g/day.

Group Type: EXPERIMENTAL

Appethyl®

Intervention Type: DIETARY_SUPPLEMENT

Spinach extract, capsules, 5g/day, 26 weeks.

Placebo

Participants are instructed to ingest 10 capsules daily and they are instructed to swallow the capsules in whole with a glass of water with/during lunchtime throughout the study period of 26 weeks.

Each capsule contain 0.5 g placebo, and the daily intake is 5 g/day.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

Pea protein, capsules, 5g/day, 26 weeks.

Interventions

Appethyl®

Spinach extract, capsules, 5g/day, 26 weeks.

Intervention Type: DIETARY_SUPPLEMENT

Placebo

Pea protein, capsules, 5g/day, 26 weeks.

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Male and women Age between 18-65 years
• BMI ≥25.0-35.9 kg/m^2
• Prediabetes (defined according to ADA with a fasting plasma glucose of 5.6 mmol/L to <7.0 mmol/L)
• Provided voluntary written informed consent

Exclusion Criteria

• Non-covid-19 vaccinated
• Known diseases which may affect energy expenditure and/or satiation/satiety/food intake
• History or diagnosis of eating disorder
• Any physical abnormality or medical condition which might have impact on following the dietary regimen
• Psychiatric disorders i.e. schizophrenia, bipolar disease or depression with hospitalization within the last 6 months
• Diabetes mellitus (type 1 and 2)
• History or diagnosis of cardiovascular disease, chronic kidney disease, liver disease and cancer
• Known systolic blood pressure above 160 mmHg and/or diastolic blood pressure above 100 mmHg whether on or off treatment for hypertension. If being treated, stable treatment (i.e. no change in treatment, either dose, type of medication or other changes) within last three months is required
• Active inflammatory bowel disease, celiac disease, chronic pancreatitis or other disorder potentially causing malabsorption
• Systemic treatment with glucocorticoids inhalations and creams etc. is allowed
• Previous bariatric surgery or intention to undergo bariatric surgery within the next 12 months
• History of extensive small or large bowel resection
• Known endocrine origin of obesity (except for treated hypothyroidism)
• Transmissible blood-borne diseases e.g. hepatitis B, HIV
• Any recent surgical procedure not fully recovered (as judged by the investigator)
• Current use of prescription medication or use within the previous month that has the potential of affecting body weight
• Current use of other prescription medication that does not affect body weight should have been stable for the past three months and expected to be stable during the study
• Concurrent therapy with immunosuppressive drugs or cytotoxic agents
• Hemoglobin concentration below local laboratory reference values (i.e. anemia)
• Being lactating, pregnant or planning to become pregnant within the study period
• Weight changes ± 5% three months prior inclusion
• Dietary patterns interfering with the study protocol, as judged by the investigator, two months prior inclusion, during the study or plans to initiate during the study
• Use of pre- and probiotic products (incl. fiber supplements) within one month prior to study initiation as well as during the study (except psyllium 10 g/day)
• Use of dietary supplementation should be stable three months prior to study initiation as well as during the study
• Severe food allergies and food intolerances expected to interfere with the study
• Intolerance, allergy or dislike of intervention products (e.g. pea allergy)
• Engagement in elite sports or similar strenuous exercise ≥5 h/week
• Blood donation or transfusion within the past month before screening
• Planned blood donation for other purpose than this study during participation
• Consumption of alcohol corresponding to >2 (for men) and >1 (for women) units/day
• Drug abuse, as judged by the investigator, within the previous 12 months
• Psychological or behavioral problems which, in the judgement of the investigator, would lead to difficulty in complying with the study protocol
• Participation in other clinical trials within the past three months or intention to do so during the study, which are likely to affect the present study
• Unable to consume the interventional product for religious reasons, swallowing disorders, other physiological reasons or any other reasons for not being able to follow the recommended diet
• Inability or unwillingness to give written informed consent or communicate with study personnel
• Inability or unwillingness to follow the study protocol and instructions given by the study personnel
• Illiteracy or inadequate understanding of Danish/Scandinavia
• Any other condition that judged by the investigator may interfere with the adherence to the study protocol

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Greenleaf Medical AB, Lund, Sweden

UNKNOWN

Sponsor Role: collaborator

Lund University

OTHER

Sponsor Role: collaborator

University of Copenhagen

OTHER

Sponsor Role: lead

Responsible Party

Faidon Magkos

Principal Investigator, Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Faidon Magkos, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Copenhagen

Locations

University of Copenhagen

Frederiksberg, DK, Denmark

Countries

Denmark

Other Identifiers

H-21045373

Identifier Type: REGISTRY

Identifier Source: secondary_id

B368

Identifier Type: -

Identifier Source: org_study_id